UCB SA (UCB.BR) Fundamental Analysis & Valuation
EBR:UCB • BE0003739530
Current stock price
239 EUR
-7.3 (-2.96%)
Last:
This UCB.BR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. UCB.BR Profitability Analysis
1.1 Basic Checks
- In the past year UCB was profitable.
- UCB had a positive operating cash flow in the past year.
- UCB had positive earnings in each of the past 5 years.
- In the past 5 years UCB always reported a positive cash flow from operatings.
1.2 Ratios
- UCB's Return On Assets of 8.58% is fine compared to the rest of the industry. UCB outperforms 68.63% of its industry peers.
- UCB's Return On Equity of 14.34% is fine compared to the rest of the industry. UCB outperforms 62.75% of its industry peers.
- The Return On Invested Capital of UCB (12.94%) is better than 64.71% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for UCB is significantly below the industry average of 13.61%.
- The last Return On Invested Capital (12.94%) for UCB is above the 3 year average (7.24%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.58% | ||
| ROE | 14.34% | ||
| ROIC | 12.94% |
ROA(3y)5.64%
ROA(5y)5.4%
ROE(3y)9.59%
ROE(5y)9.2%
ROIC(3y)7.24%
ROIC(5y)7.33%
1.3 Margins
- With an excellent Profit Margin value of 20.13%, UCB belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
- In the last couple of years the Profit Margin of UCB has grown nicely.
- Looking at the Operating Margin, with a value of 25.98%, UCB is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
- UCB's Operating Margin has improved in the last couple of years.
- The Gross Margin of UCB (74.29%) is better than 68.63% of its industry peers.
- UCB's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.98% | ||
| PM (TTM) | 20.13% | ||
| GM | 74.29% |
OM growth 3Y27.72%
OM growth 5Y4.58%
PM growth 3Y38.49%
PM growth 5Y8.01%
GM growth 3Y2.17%
GM growth 5Y-0.06%
2. UCB.BR Health Analysis
2.1 Basic Checks
- UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for UCB remains at a similar level compared to 1 year ago.
- UCB has more shares outstanding than it did 5 years ago.
- UCB has a better debt/assets ratio than last year.
2.2 Solvency
- UCB has an Altman-Z score of 5.53. This indicates that UCB is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.53, UCB belongs to the top of the industry, outperforming 80.39% of the companies in the same industry.
- The Debt to FCF ratio of UCB is 1.22, which is an excellent value as it means it would take UCB, only 1.22 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of UCB (1.22) is better than 86.27% of its industry peers.
- UCB has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
- UCB has a Debt to Equity ratio of 0.20. This is in the better half of the industry: UCB outperforms 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.22 | ||
| Altman-Z | 5.53 |
ROIC/WACC1.63
WACC7.94%
2.3 Liquidity
- A Current Ratio of 1.38 indicates that UCB should not have too much problems paying its short term obligations.
- UCB has a Current ratio (1.38) which is in line with its industry peers.
- UCB has a Quick Ratio of 1.04. This is a normal value and indicates that UCB is financially healthy and should not expect problems in meeting its short term obligations.
- UCB's Quick ratio of 1.04 is in line compared to the rest of the industry. UCB outperforms 54.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.04 |
3. UCB.BR Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 100.60% over the past year.
- Measured over the past years, UCB shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.26% on average per year.
- Looking at the last year, UCB shows a very strong growth in Revenue. The Revenue has grown by 25.83%.
- Measured over the past years, UCB shows a small growth in Revenue. The Revenue has been growing by 7.68% on average per year.
EPS 1Y (TTM)100.6%
EPS 3Y31.73%
EPS 5Y13.26%
EPS Q2Q%123.53%
Revenue 1Y (TTM)25.83%
Revenue growth 3Y11.95%
Revenue growth 5Y7.68%
Sales Q2Q%26.57%
3.2 Future
- Based on estimates for the next years, UCB will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.75% on average per year.
- The Revenue is expected to grow by 10.92% on average over the next years. This is quite good.
EPS Next Y5.7%
EPS Next 2Y16.16%
EPS Next 3Y18.54%
EPS Next 5Y16.75%
Revenue Next Year11.39%
Revenue Next 2Y11.92%
Revenue Next 3Y11.93%
Revenue Next 5Y10.92%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. UCB.BR Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 23.92, which indicates a rather expensive current valuation of UCB.
- UCB's Price/Earnings ratio is in line with the industry average.
- UCB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.42.
- With a Price/Forward Earnings ratio of 22.63, UCB is valued on the expensive side.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of UCB is on the same level as its industry peers.
- The average S&P500 Price/Forward Earnings ratio is at 22.24. UCB is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.92 | ||
| Fwd PE | 22.63 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as UCB.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of UCB is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.24 | ||
| EV/EBITDA | 17.93 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates UCB does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of UCB may justify a higher PE ratio.
- A more expensive valuation may be justified as UCB's earnings are expected to grow with 18.54% in the coming years.
PEG (NY)4.2
PEG (5Y)1.8
EPS Next 2Y16.16%
EPS Next 3Y18.54%
5. UCB.BR Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.39%, UCB is not a good candidate for dividend investing.
- UCB's Dividend Yield is comparable with the industry average which is at 1.89.
- Compared to an average S&P500 Dividend Yield of 1.81, UCB's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.39% |
5.2 History
- The dividend of UCB has a limited annual growth rate of 2.20%.
Dividend Growth(5Y)2.2%
Div Incr Years7
Div Non Decr Years7
5.3 Sustainability
- 16.94% of the earnings are spent on dividend by UCB. This is a low number and sustainable payout ratio.
- The dividend of UCB is growing, but earnings are growing more, so the dividend growth is sustainable.
DP16.94%
EPS Next 2Y16.16%
EPS Next 3Y18.54%
UCB.BR Fundamentals: All Metrics, Ratios and Statistics
EBR:UCB (4/24/2026, 7:00:00 PM)
239
-7.3 (-2.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)07-26 2026-07-26
Inst Owners40.85%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap46.49B
Revenue(TTM)7.74B
Net Income(TTM)1.56B
Analysts74.81
Price Target288.71 (20.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.39% |
Yearly Dividend1.39
Dividend Growth(5Y)2.2%
DP16.94%
Div Incr Years7
Div Non Decr Years7
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.04%
PT rev (3m)9.43%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.66%
EPS NY rev (3m)3.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.41%
Revenue NY rev (3m)0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.92 | ||
| Fwd PE | 22.63 | ||
| P/S | 6.01 | ||
| P/FCF | 25.24 | ||
| P/OCF | 20.29 | ||
| P/B | 4.28 | ||
| P/tB | 19.96 | ||
| EV/EBITDA | 17.93 |
EPS(TTM)9.99
EY4.18%
EPS(NY)10.56
Fwd EY4.42%
FCF(TTM)9.47
FCFY3.96%
OCF(TTM)11.78
OCFY4.93%
SpS39.8
BVpS55.87
TBVpS11.97
PEG (NY)4.2
PEG (5Y)1.8
Graham Number112.062 (-53.11%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.58% | ||
| ROE | 14.34% | ||
| ROCE | 14.62% | ||
| ROIC | 12.94% | ||
| ROICexc | 15.9% | ||
| ROICexgc | 66.94% | ||
| OM | 25.98% | ||
| PM (TTM) | 20.13% | ||
| GM | 74.29% | ||
| FCFM | 23.8% |
ROA(3y)5.64%
ROA(5y)5.4%
ROE(3y)9.59%
ROE(5y)9.2%
ROIC(3y)7.24%
ROIC(5y)7.33%
ROICexc(3y)8.58%
ROICexc(5y)8.54%
ROICexgc(3y)38.33%
ROICexgc(5y)45.6%
ROCE(3y)8.18%
ROCE(5y)8.29%
ROICexgc growth 3Y18.32%
ROICexgc growth 5Y-5.98%
ROICexc growth 3Y44.94%
ROICexc growth 5Y7.84%
OM growth 3Y27.72%
OM growth 5Y4.58%
PM growth 3Y38.49%
PM growth 5Y8.01%
GM growth 3Y2.17%
GM growth 5Y-0.06%
F-Score9
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.22 | ||
| Debt/EBITDA | 0.83 | ||
| Cap/Depr | 71.61% | ||
| Cap/Sales | 5.8% | ||
| Interest Coverage | 15.71 | ||
| Cash Conversion | 86.85% | ||
| Profit Quality | 118.23% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z | 5.53 |
F-Score9
WACC7.94%
ROIC/WACC1.63
Cap/Depr(3y)55.86%
Cap/Depr(5y)76.64%
Cap/Sales(3y)5.68%
Cap/Sales(5y)6.46%
Profit Quality(3y)111.45%
Profit Quality(5y)122.7%
High Growth Momentum
Growth
EPS 1Y (TTM)100.6%
EPS 3Y31.73%
EPS 5Y13.26%
EPS Q2Q%123.53%
EPS Next Y5.7%
EPS Next 2Y16.16%
EPS Next 3Y18.54%
EPS Next 5Y16.75%
Revenue 1Y (TTM)25.83%
Revenue growth 3Y11.95%
Revenue growth 5Y7.68%
Sales Q2Q%26.57%
Revenue Next Year11.39%
Revenue Next 2Y11.92%
Revenue Next 3Y11.93%
Revenue Next 5Y10.92%
EBIT growth 1Y40.24%
EBIT growth 3Y42.99%
EBIT growth 5Y12.61%
EBIT Next Year63.68%
EBIT Next 3Y33.12%
EBIT Next 5Y25.36%
FCF growth 1Y100.22%
FCF growth 3Y35.04%
FCF growth 5Y20.27%
OCF growth 1Y84.46%
OCF growth 3Y26.98%
OCF growth 5Y16.21%
UCB SA / UCB.BR Fundamental Analysis FAQ
What is the fundamental rating for UCB stock?
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.
Can you provide the valuation status for UCB SA?
ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UCB.BR). This can be considered as Overvalued.
What is the profitability of UCB stock?
UCB SA (UCB.BR) has a profitability rating of 7 / 10.
What is the valuation of UCB SA based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 23.92 and the Price/Book (PB) ratio is 4.28.
Can you provide the dividend sustainability for UCB stock?
The dividend rating of UCB SA (UCB.BR) is 4 / 10 and the dividend payout ratio is 16.94%.